FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034012312> ?p ?o ?g. }

• W2034012312 endingPage "313" @default.
• W2034012312 startingPage "307" @default.
• W2034012312 abstract "Tumour angiogenesis is initiated by angiogenic factors that are produced in large amounts by hypoxic tumour cells. The inhibition of this step may lead to tumour-specific antiangiogenesis because normal tissues are not usually hypoxic. On the other hand, blocking a biological function of endothelial cells is known to result in angiogenic inhibition. To produce a tumour-specific and powerful antiangiogenesis, we determined whether potent angiogenic inhibition could be achieved by inhibiting the production of angiogenic factors by hypoxic tumour cells and simultaneously blocking certain angiogenic steps in endothelial cells under normoxia. We focused on the 2-nitroimidazole moiety, which is easily incorporated into hypoxic cells and exhibits its cytotoxicity as hypoxic cytotoxin. We designed and synthesised 2-nitroimidazole derivatives designated as KIN compounds, and investigated their antiangiogenic activities under normoxia using a chick embryo chorioallantoic membrane. KIN-841 (2-nitroimidazole 1-acetylhydroxamate) showed a potent angiogenic inhibition in a dose-dependent manner. This compound inhibited the proliferation of bovine pulmonary arterial endothelial (BPAE) cells more strongly than that of tumour cells, such as Lewis lung carcinoma (3LL) cells, under normoxia. The inhibition of cell proliferation by KIN-841 under hypoxia increased about five-fold compared to that under normoxia. Moreover, under hypoxia, KIN-841 significantly decreased the excessive production of vascular endothelial cell growth factors induced by 3LL cells as determined by tritium-labelled thymidine ([(3)H]thymidine) incorporation into BPAE cells and by ELISA. Intraperitoneal administration of KIN-841 suppressed 3LL-cell-induced in vivo angiogenesis in the mouse dorsal air sac system. These results indicate that the regulation of the production of angiogenic factors by hypoxic tumour cells is a useful target for tumour-specific angiogenesis inhibition, and that KIN-841, which causes simultaneous direct inhibition of endothelial cell function and production of angiogenic factors by hypoxic tumour cells, is a very potent inhibitor of tumour-specific angiogenesis. Thus, the potential for clinical use of KIN-841 as an antitumour drug is very high." @default.
• W2034012312 created "2016-06-24" @default.
• W2034012312 creator A5002280001 @default.
• W2034012312 creator A5005250738 @default.
• W2034012312 creator A5023857268 @default.
• W2034012312 creator A5026151137 @default.
• W2034012312 creator A5034378539 @default.
• W2034012312 creator A5044067884 @default.
• W2034012312 creator A5066108552 @default.
• W2034012312 creator A5088669806 @default.
• W2034012312 date "2003-01-01" @default.
• W2034012312 modified "2023-10-14" @default.
• W2034012312 title "A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors" @default.
• W2034012312 cites W1481581408 @default.
• W2034012312 cites W1566310902 @default.
• W2034012312 cites W1675889352 @default.
• W2034012312 cites W1855071553 @default.
• W2034012312 cites W1910357306 @default.
• W2034012312 cites W1912376315 @default.
• W2034012312 cites W1965910664 @default.
• W2034012312 cites W1971607332 @default.
• W2034012312 cites W1978471137 @default.
• W2034012312 cites W1992285766 @default.
• W2034012312 cites W1997563706 @default.
• W2034012312 cites W2012851453 @default.
• W2034012312 cites W2015344488 @default.
• W2034012312 cites W2015412192 @default.
• W2034012312 cites W2054868631 @default.
• W2034012312 cites W2055522497 @default.
• W2034012312 cites W2055953269 @default.
• W2034012312 cites W2059489770 @default.
• W2034012312 cites W2069135793 @default.
• W2034012312 cites W2077266389 @default.
• W2034012312 cites W2109561684 @default.
• W2034012312 cites W2114697060 @default.
• W2034012312 cites W2116444357 @default.
• W2034012312 cites W2132700864 @default.
• W2034012312 cites W2142778735 @default.
• W2034012312 cites W2144572512 @default.
• W2034012312 cites W2156022862 @default.
• W2034012312 cites W2167229055 @default.
• W2034012312 cites W2170124424 @default.
• W2034012312 cites W2404019854 @default.
• W2034012312 cites W2419021405 @default.
• W2034012312 cites W4245635197 @default.
• W2034012312 cites W2414902991 @default.
• W2034012312 doi "https://doi.org/10.1038/sj.bjc.6600667" @default.
• W2034012312 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2377039" @default.
• W2034012312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12610518" @default.
• W2034012312 hasPublicationYear "2003" @default.
• W2034012312 type Work @default.
• W2034012312 sameAs 2034012312 @default.
• W2034012312 citedByCount "22" @default.
• W2034012312 countsByYear W20340123122012 @default.
• W2034012312 countsByYear W20340123122013 @default.
• W2034012312 countsByYear W20340123122014 @default.
• W2034012312 countsByYear W20340123122019 @default.
• W2034012312 countsByYear W20340123122022 @default.
• W2034012312 crossrefType "journal-article" @default.
• W2034012312 hasAuthorship W2034012312A5002280001 @default.
• W2034012312 hasAuthorship W2034012312A5005250738 @default.
• W2034012312 hasAuthorship W2034012312A5023857268 @default.
• W2034012312 hasAuthorship W2034012312A5026151137 @default.
• W2034012312 hasAuthorship W2034012312A5034378539 @default.
• W2034012312 hasAuthorship W2034012312A5044067884 @default.
• W2034012312 hasAuthorship W2034012312A5066108552 @default.
• W2034012312 hasAuthorship W2034012312A5088669806 @default.
• W2034012312 hasBestOaLocation W20340123121 @default.
• W2034012312 hasConcept C109316439 @default.
• W2034012312 hasConcept C121608353 @default.
• W2034012312 hasConcept C123012128 @default.
• W2034012312 hasConcept C150903083 @default.
• W2034012312 hasConcept C178790620 @default.
• W2034012312 hasConcept C185592680 @default.
• W2034012312 hasConcept C202751555 @default.
• W2034012312 hasConcept C203014093 @default.
• W2034012312 hasConcept C207001950 @default.
• W2034012312 hasConcept C2777847059 @default.
• W2034012312 hasConcept C2779013556 @default.
• W2034012312 hasConcept C2780394083 @default.
• W2034012312 hasConcept C502942594 @default.
• W2034012312 hasConcept C540031477 @default.
• W2034012312 hasConcept C54355233 @default.
• W2034012312 hasConcept C55493867 @default.
• W2034012312 hasConcept C62112901 @default.
• W2034012312 hasConcept C7836513 @default.
• W2034012312 hasConcept C81885089 @default.
• W2034012312 hasConcept C86803240 @default.
• W2034012312 hasConcept C95444343 @default.
• W2034012312 hasConcept C97230052 @default.
• W2034012312 hasConcept C98274493 @default.
• W2034012312 hasConceptScore W2034012312C109316439 @default.
• W2034012312 hasConceptScore W2034012312C121608353 @default.
• W2034012312 hasConceptScore W2034012312C123012128 @default.
• W2034012312 hasConceptScore W2034012312C150903083 @default.
• W2034012312 hasConceptScore W2034012312C178790620 @default.
• W2034012312 hasConceptScore W2034012312C185592680 @default.
• W2034012312 hasConceptScore W2034012312C202751555 @default.

• next